Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc.（ORMP）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ORMP · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
0
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Oramed Pharmaceuticals Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ORMP 季度内部人买卖趋势
ORMP 内幕交易卖出 · ORMP 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ORMP CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ORMP 高管卖出股份 · ORMP 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Mar 30, 2026 | KIDRON NADAV President and CEO · Director | Other | 44,818 | $148K | Form 4 |
| Mar 30, 2026 | Kidron Miriam Chief Scientific Officer · Director | Other | 435,084 | $1.44M⚡ | Form 4 |
| Mar 17, 2026 | Kidron Miriam Chief Scientific Officer · Director | Award | 119,558 | — | Form 4 |
| Mar 17, 2026 | KIDRON NADAV President and CEO · Director | Award | 167,005 | — | Form 4 |
| Mar 17, 2026 | Hexter Joshua COO & CBO | Award | 95,889 | — | Form 4 |
| Mar 17, 2026 | Gabay Avraham CFO | Award | 95,889 | — | Form 4 |
| Mar 12, 2026 | KIDRON NADAV President and CEO · Director | Gift | 100,000 | — | Form 4 |
| Jan 22, 2026 | Hexter Joshua COO & CBO | Option | 19,000 | — | Form 4 |
| Jan 22, 2026 | Kidron Miriam Chief Scientific Officer · Director | Option | 19,000 | — | Form 4 |
| Jan 22, 2026 | Gabay Avraham CFO | Option | 19,000 | — | Form 4 |
| Jan 22, 2026 | KIDRON NADAV President and CEO · Director | Option | 109,000 | — | Form 4 |
| Jan 14, 2026 | Kidron Miriam Chief Scientific Officer · Director | Gift | 86,166 | — | Form 4 |
| Dec 31, 2025 | Reznick Yehuda Director | Award | 6,250 | — | Form 4 |
| Dec 31, 2025 | Reznick Yehuda Director | Award | 30,000 | $360 | Form 4 |
| Dec 31, 2025 | KIDRON NADAV President and CEO · Director | Award | 327,000 | — | Form 4 |
| Dec 31, 2025 | KIDRON NADAV President and CEO · Director | Award | 232,640 | — | Form 4 |
| Dec 31, 2025 | Kidron Miriam Chief Scientific Officer · Director | Award | 115,000 | — | Form 4 |
| Dec 31, 2025 | Kidron Miriam Chief Scientific Officer · Director | Award | 121,331 | — | Form 4 |
| Dec 31, 2025 | Hexter Joshua COO & CBO | Award | 115,000 | — | Form 4 |
| Dec 31, 2025 | Hexter Joshua COO & CBO | Award | 97,328 | — | Form 4 |
| Dec 31, 2025 | Shapiro Benjamin Director | Award | 3,500 | — | Form 4 |
| Dec 31, 2025 | Shapiro Benjamin Director | Award | 30,000 | $360 | Form 4 |
| Dec 31, 2025 | Mayer Arie Director | Award | 4,900 | — | Form 4 |
| Dec 31, 2025 | Mayer Arie Director | Award | 30,000 | $360 | Form 4 |
| Dec 31, 2025 | Aghion Daniel Director | Award | 6,250 | — | Form 4 |
Kidron Miriam
Chief Scientific Officer · Director
日期
Mar 30
股数
435,084
均价
$3.31
总金额
$1.44M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ORMP 内幕交易
ORMP 内幕交易
Oramed Pharmaceuticals Inc.（ORMP）内幕交易数据来源于公司内部人（包括KIDRON NADAV (President and CEO · Director), Kidron Miriam (Chief Scientific Officer · Director), Hexter Joshua (COO & CBO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ORMP内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Oramed Pharmaceuticals Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ORMP 内幕交易 · 5个问题Oramed Pharmaceuticals Inc.（ORMP）的内部人包括高管和董事，如KIDRON NADAV (President and CEO · Director), Kidron Miriam (Chief Scientific Officer · Director), Hexter Joshua (COO & CBO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026